Literature DB >> 35819155

Comprehensive characterization of antral and pyloric contractions by high resolution manometry: applied physiology in suspected gastroparesis.

Ting Zheng1, Joelle BouSaba1, Wassel Sannaa1, Deborah J Eckert1, Duane D Burton1, Michael Camilleri1.   

Abstract

Delayed gastric emptying may result from diverse pathophysiological mechanisms including antral hypomotility and pylorospasm. With increasing use of gastric peroral endoscopic myotomy and preliminary evidence of efficacy, our aim was to assess the motor functions of the distal antrum and pylorus in patients with symptoms of gastroparesis using high-resolution antropyloroduodenal manometry (HR-ADM). Sixteen patients with symptoms suggestive of gastroparesis underwent HR-ADM with 13 sensors, 1 cm apart, placed across the antropyloroduodenal (APD) junction and 2 sensors, 10 cm apart, in descending and distal duodenum. The 1-h postprandial motility was quantitated as contraction frequency/minute, average amplitude, and motility index (MI). Six healthy volunteers served as controls. In the patient group, the HR-ADM identified postprandial antral hypomotility, isolated pyloric pressure waves, and tonic elevation of baseline pressure in pylorus. Patients had significantly reduced frequency of the full-hour postprandial antral contractions/minute compared with healthy volunteers [1.52 (0.97, 1.67) vs. 2.04 (1.70, 2.67), P = 0.005], as well as reduced MI [9.65 (8.29, 10.31) vs. 11.04 (10.65, 11.63), P = 0.002]. The average contraction amplitude was numerically, but not significantly reduced [51.9 (21.9, 74.9) vs. 73.0 (59.8, 82.7), P = 0.14]. Bland-Altman plots showed similar distribution of antral contraction frequency and MI during the first and second postprandial 30-min periods for both patients and controls. High-resolution ADM can characterize a variety of postprandial antral contractile and pyloric motility dysfunctions. This technique shows promise to provide guidance for the selection of optimal treatment of patients with gastroparesis.NEW & NOTEWORTHY Current selection of different treatments for patients with gastroparesis is empiric or based on trial and error, though pyloric distensibility and diameter may predict response to pyloric interventions. High-resolution antropyloroduodenal manometry (HR-ADM) can characterize a variety of postprandial antral contractile and pyloric motility dysfunctions in patients with suspected gastroparesis. HR-ADM shows promise to provide guidance for selection and individualization of treatments such as prokinetic agents or pyloric interventions for patients with gastroparesis based on documented pathophysiology.

Entities:  

Keywords:  dysmotility; gastric; motility; pylorospasm

Mesh:

Year:  2022        PMID: 35819155      PMCID: PMC9448275          DOI: 10.1152/ajpgi.00119.2022

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.871


  28 in total

1.  Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine.

Authors:  Thomas L Abell; Michael Camilleri; Kevin Donohoe; William L Hasler; Henry C Lin; Alan H Maurer; Richard W McCallum; Thomas Nowak; Martin L Nusynowitz; Henry P Parkman; Paul Shreve; Lawrence A Szarka; William J Snape; Harvey A Ziessman
Journal:  Am J Gastroenterol       Date:  2007-11-19       Impact factor: 10.864

2.  Pyloric distensibility measurement predicts symptomatic response to intrapyloric botulinum toxin injection.

Authors:  Charlotte Desprez; Chloé Melchior; Fabien Wuestenberghs; Alberto Zalar; Jérémie Jacques; Anne-Marie Leroi; Guillaume Gourcerol
Journal:  Gastrointest Endosc       Date:  2019-04-25       Impact factor: 9.427

3.  Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants.

Authors:  M Camilleri; J Iturrino; A E Bharucha; D Burton; A Shin; I-D Jeong; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2012-07-02       Impact factor: 3.598

4.  Botulinum toxin A for the treatment of delayed gastric emptying.

Authors:  Frank K Friedenberg; Amiya Palit; Henry P Parkman; Alexandra Hanlon; Deborah B Nelson
Journal:  Am J Gastroenterol       Date:  2007-12-05       Impact factor: 10.864

5.  Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings.

Authors:  V Stanghellini; M Camilleri; J R Malagelada
Journal:  Gut       Date:  1987-01       Impact factor: 23.059

6.  Gastrointestinal motility disturbances in patients with orthostatic hypotension.

Authors:  M Camilleri; J R Malagelada; V Stanghellini; R D Fealey; S G Sheps
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

7.  Relationship between impaired gastric emptying and abnormal gastrointestinal motility.

Authors:  M Camilleri; M L Brown; J R Malagelada
Journal:  Gastroenterology       Date:  1986-07       Impact factor: 22.682

8.  Gastric per-oral endoscopic myotomy (G-POEM) for refractory gastroparesis: results from an international prospective trial.

Authors:  Kia Vosoughi; Yervant Ichkhanian; Petros Benias; Larry Miller; A Aziz Aadam; Joseph R Triggs; Ryan Law; William Hasler; Nicole Bowers; Dalton Chaves; Alberto M Ponte-Neto; Peter Draganov; Dennis Yang; Maan El Halabi; Omid Sanaei; Olaya Isabella Brewer Gutierrez; Robert Stephen Bulat; John Pandolfino; Mouen Khashab
Journal:  Gut       Date:  2021-03-19       Impact factor: 23.059

9.  Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial.

Authors:  Jan Martinek; Rastislav Hustak; Jan Mares; Zuzana Vackova; Julius Spicak; Eva Kieslichova; Marie Buncova; Daniel Pohl; Sunil Amin; Jan Tack
Journal:  Gut       Date:  2022-04-25       Impact factor: 31.793

10.  Relationship of motor mechanisms to gastroparesis symptoms: toward individualized treatment.

Authors:  Michael Camilleri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-02-10       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.